J. Moore

3.3k total citations · 1 hit paper
25 papers, 2.4k citations indexed

About

J. Moore is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J. Moore has authored 25 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 8 papers in Immunology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J. Moore's work include Immunotherapy and Immune Responses (8 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). J. Moore is often cited by papers focused on Immunotherapy and Immune Responses (8 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). J. Moore collaborates with scholars based in United Kingdom, Sweden and United States. J. Moore's co-authors include Helen R. Griffiths, I. Craig Henderson, Debu Tripathy, Paul Peter Rosen, Nancy T. Sklarin, Andrew D. Seidman, Sharon A. Baughman, José Baselga, Larry Norton and Christopher C. Benz and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

J. Moore

24 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

1996 1.1k citations José Baselga, Debu Tripathy et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Moore United Kingdom	14	1.4k	917	813	383	314	25	2.4k
Jean‐Pierre Mach Switzerland	32	1.2k 0.8×	1.9k 2.1×	1.3k 1.5×	944 2.5×	167 0.5×	67	3.3k
Emilian Racila United States	21	839 0.6×	438 0.5×	436 0.5×	712 1.9×	274 0.9×	45	2.0k
Agamemnon A. Epenetos United Kingdom	30	665 0.5×	1.4k 1.5×	1.1k 1.3×	407 1.1×	104 0.3×	84	2.5k
Christoph Schliemann Germany	30	1.2k 0.9×	637 0.7×	1.0k 1.3×	573 1.5×	145 0.5×	120	2.8k
Graeme J. Dougherty United States	18	472 0.3×	355 0.4×	741 0.9×	603 1.6×	203 0.6×	44	2.0k
Vincent R. Zurawski United States	28	537 0.4×	761 0.8×	1.0k 1.2×	677 1.8×	103 0.3×	44	3.2k
Gundram Jung Germany	31	1.4k 1.0×	729 0.8×	871 1.1×	1.7k 4.4×	120 0.4×	114	2.9k
Daniel C. Maneval United States	29	1.9k 1.4×	547 0.6×	1.5k 1.8×	477 1.2×	236 0.8×	75	3.5k
Damian J. Green United States	27	1.4k 1.0×	683 0.7×	922 1.1×	403 1.1×	241 0.8×	126	2.6k
Marleen Keyaerts Belgium	30	1.4k 1.0×	1.9k 2.1×	1.1k 1.4×	769 2.0×	315 1.0×	70	3.1k

Countries citing papers authored by J. Moore

Since Specialization

Citations

This map shows the geographic impact of J. Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Moore more than expected).

Fields of papers citing papers by J. Moore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Moore. The network helps show where J. Moore may publish in the future.

Co-authorship network of co-authors of J. Moore

This figure shows the co-authorship network connecting the top 25 collaborators of J. Moore. A scholar is included among the top collaborators of J. Moore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Moore. J. Moore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pucher, Philip H., Annie E. Coombes, J. Moore, et al.. (2022). Patient perspectives on key symptoms and preferences for follow-up after upper gastro-intestinal cancer surgery. Supportive Care in Cancer. 30(6). 5269–5275. 1 indexed citations

Price, Timothy, Christos S. Karapetis, Gonzalo Tapia Rico, et al.. (2016). Brain metastasis in advanced colorectal cancer: Results from the South Australian metastatic colorectal cancer (SAmCRC) registry. Annals of Oncology. 27. vi160–vi160. 3 indexed citations

Vaughan, Matthew, J. Moore, SR Johnston, et al.. (2000). GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): A phase I trial in melanoma. Annals of Oncology. 11(9). 1183–1190. 13 indexed citations

Gregory, R.K., Mark Hill, J. Moore, et al.. (2000). Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy. European Journal of Cancer. 36(4). 503–507. 17 indexed citations

Allen, Mark, Matthew Vaughan, Andrew Webb, et al.. (2000). Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study. British Journal of Cancer. 83(8). 980–985. 49 indexed citations

Baselga, José, Debu Tripathy, J. Mendelsohn, et al.. (1999). Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.. PubMed. 26(4 Suppl 12). 78–83. 229 indexed citations

Palmer, Kay, J. Moore, Robert C. Rees, et al.. (1999). Gene Therapy with Autologous, Interleukin 2-Secreting Tumor Cells in Patients with Malignant Melanoma. Human Gene Therapy. 10(8). 1261–1268. 66 indexed citations

Johnston, SR, et al.. (1998). Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-α) and interleukin (IL-2) in patients with metastatic melanoma. British Journal of Cancer. 77(8). 1280–1286. 65 indexed citations

Mainwaring, Paul N., Jenny C. Chang, J. Moore, et al.. (1997). Differential responses to chemoimmunotherapy in patients with metastatic malignant melanoma. European Journal of Cancer. 33(9). 1388–1392. 2 indexed citations

10.

Savage, Philip, et al.. (1997). A phase II study of continuous infusional 5-fluorouracil (5-FU) and subcutaneous interleukin-2 (IL-2) in metastatic renal cancer. European Journal of Cancer. 33(7). 1149–1151. 10 indexed citations

11.

Baselga, José, Debu Tripathy, John Mendelsohn, et al.. (1996). Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.. Journal of Clinical Oncology. 14(3). 737–744. 1088 indexed citations breakdown →

12.

Modjtahedi, Helmout, Tamas Hickish, Margery Nicolson, et al.. (1996). Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. British Journal of Cancer. 73(2). 228–235. 82 indexed citations

13.

Savage, Philip, et al.. (1996). A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. British Journal of Cancer. 74(9). 1482–1486. 93 indexed citations

14.

A’Hern, Roger, et al.. (1996). A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma. British Journal of Cancer. 74(7). 1109–1113. 7 indexed citations

15.

Gooding, Roger, et al.. (1995). Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2. British Journal of Cancer. 72(2). 452–455. 55 indexed citations

16.

O’Brien, Mary, John B. Schofield, J. Moore, et al.. (1994). The use of cisplatin plus 5-fluorouracil chemotherapy in an unselected group of patients with recurrent squamous cell carcinoma of the head and neck. European Journal of Cancer Part B Oral Oncology. 30(4). 265–267. 4 indexed citations

17.

Henderson, D.C., et al.. (1993). Immune changes in peripheral blood resulting from locally directed interleukin-2 therapy in squamous cell carcinoma of the head and neck. European Journal of Cancer Part B Oral Oncology. 29(1). 29–34. 13 indexed citations

18.

McKeage, Mark J., et al.. (1993). Cisplatin, dacarbazine and tamoxifen for refractory advanced malignant melanoma. Melanoma Research. 3(1). 35–35. 1 indexed citations

19.

MacLennan, K.A., E O’Brien, J. Moore, et al.. (1992). Phase I study of intra-arterial interleukin-2 in squamous cell carcinoma of the head and neck. British Journal of Cancer. 66(2). 405–407. 9 indexed citations

20.

Griffiths, Helen R. & J. Moore. (1985). Hyperthermic Oncology 1984. International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine. 48(5). 863–864. 406 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact